|1.||Konishi, Eiji: 5 articles (11/2015 - 12/2011)|
|2.||Postow, Michael A: 5 articles (01/2015 - 01/2014)|
|3.||Yamanaka, Atsushi: 4 articles (11/2015 - 11/2012)|
|4.||Alitalo, Kari: 4 articles (08/2015 - 09/2010)|
|5.||Wolchok, Jedd D: 4 articles (08/2015 - 01/2011)|
|6.||Hondermarck, Hubert: 3 articles (10/2015 - 04/2011)|
|7.||Pardoll, Drew M: 3 articles (02/2015 - 08/2013)|
|8.||Brown, Rosalind S: 3 articles (01/2015 - 09/2004)|
|9.||Harris, Eva: 3 articles (10/2014 - 02/2013)|
|10.||Diamond, Michael S: 3 articles (01/2014 - 02/2013)|
|1.||Melanoma (Melanoma, Malignant)
02/01/2015 - "PD-L1 expression in melanoma correlates with response to PD-1 pathway-blocking antibodies. "
08/01/2014 - "Functional blocking antibodies used in adhesion and migration assays revealed that integrin αvβ3 was strongly involved in adhesion and migration only in cutaneous melanoma cells, but its role here was less pronounced than that of integrin αvβ5. "
05/01/2012 - "However, continuous investigation on the immune mediated rejection of melanoma cells has led to the development of effective antibodies blocking cytotoxic T-lymphocyte antigen-4 (CTLA-4), a critical negative regulator of the antitumor T-cell response. "
11/01/2005 - "The use of selective DR4/DR5 blocking antibodies unequivocally proved the prevalent role of DR4 in those melanoma cells, where it was expressed. "
12/01/2000 - "Moreover, the combination of anti-IL-2R beta and anti-IL-2R gamma blocking antibodies induced a significant down-regulation of cell proliferation in the three melanoma cell lines, and the combination of anti-IL-2R alpha, anti-IL-2R beta and anti-IL-2R gamma blocking antibodies inhibited IL-2-mediated growth stimulation in A375 and Hs294T cell lines. "
01/01/2015 - "Therapy of hematological cancers with antibodies blocking inhibitory receptors is expected to be highly clinically effective. "
03/01/2012 - "This nanoparticle may be an improved alternative to chemical conjugates and signal-blocking antibodies for tumor-targeted treatment."
07/15/2014 - "Recent observations in cancer clinical trials using blocking antibodies against PD-1 or CTLA4, or both, showed a high incidence of autoimmune-related side effects, confirming the important role of these pathways in human immune homeostasis. "
04/01/2012 - "Since CD200 expression on human malignancies is associated with tumor progression, CD200 blocking antibodies are currently tested in clinical trials to boost anti-tumor responses. "
10/01/2003 - "Small molecular integrin antagonists or blocking antibodies suppress angiogenesis and tumor progression in many animal models, and some of them are currently being tested in cancer clinical trials as anti-angiogenic agents. "
04/01/2012 - "Whether enhancing antibodies raised against VP4 can play a role in iterative homologous and/or heterologous CV-B infections and in the persistence of viruses within the host deserves further study."
06/01/2003 - "In this study, we investigated the role of this costimulatory pathway in resistance to Trypanosoma cruzi infection by using CD28-deficient mice and blocking antibodies against CD80 and CD86. "
11/09/2015 - "However, the concomitant induction of infection-enhancing antibodies is an unavoidable concern. "
11/01/2015 - "Their respective contributions to the initial stage of vascular remodeling and sprouting lymphangiogenesis were examined by comparing the effects of function-blocking antibodies to Ang2 or TNF, given individually or together during the first week after infection. "
10/01/2015 - "Induction of homologous and cross-reactive GII.4-specific blocking antibodies in children after GII.4 New Orleans norovirus infection."
|4.||Renal Cell Carcinoma (Grawitz Tumor)
06/01/2013 - "An overview of early-phase trial results distinguish blocking antibodies targeting inhibitory coreceptors as a highly promising approach to cancer immunotherapy for patients with advanced clear cell renal cell carcinoma. "
04/01/2014 - "PD-1/PD-1 ligand blocking antibodies can reverse the inhibition and show significant therapeutic promise in treating renal cell carcinoma (RCC), lung cancer, and melanoma. "
12/01/2014 - "The development of blocking antibodies against the inhibitory programmed death-1 (PD-1) pathway represents a clinical breakthrough in the treatment of solid tumors such as melanoma, and these agents show great promise in renal cell carcinoma (RCC). "
|5.||Psoriasis (Pustulosis Palmaris et Plantaris)
01/01/2010 - "To examine the possible implication of S100A4 in the pathogenesis of psoriasis, we analyzed the effect of S100A4 blocking antibodies in a human psoriasis xenograft SCID mouse model and observed a significant reduction of the epidermal thickness and impairment in cell proliferation and dermal vascularization. "
07/01/2012 - "CD28/CD80 seems to be crucial in stimulating T cell activation and inflammation in psoriasis, and its inhibition by CTLA4 analogs or by anti-CD28 blocking antibodies is effective against psoriasis. "
10/01/2015 - "Antibodies blocking the action of IL-17 have already been approved to treat patients with psoriasis and it is expected that they may also benefit patients with other rheumatic diseases. "
|2.||Complement System Proteins (Complement)
|3.||Protein Kinases (Protein Kinase)
|4.||Nerve Growth Factor (NGF)
|5.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|6.||Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)
|7.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|9.||Cell Adhesion Molecules
|2.||Drug Therapy (Chemotherapy)
|3.||Heterologous Transplantation (Xenotransplantation)